Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure

Three major cardiovascular outcome trials (CVOTs) with a new class of antidiabetic drugs - sodium-glucose cotransporter 2 (SGLT2) inhibitors (EMPA-REG OUTCOME trial with empagliflozin, CANVAS Program with canagliflozin, DECLARE-TIMI 58 with dapagliflozin) unexpectedly showed that cardiovascular outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Grubić Rotkvić, Petra, Cigrovski Berković, Maja, Bulj, Nikola, Rotkvić, Luka, Ćelap, Ivana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415232/
https://www.ncbi.nlm.nih.gov/pubmed/32843930
http://dx.doi.org/10.4239/wjd.v11.i7.269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415232/
https://www.ncbi.nlm.nih.gov/pubmed/32843930
http://dx.doi.org/10.4239/wjd.v11.i7.269

Ejemplares similares